Alzamend Neuro, Inc. (ALZN)
Market Cap | 3.12M |
Revenue (ttm) | n/a |
Net Income (ttm) | -12.40M |
Shares Out | 7.89M |
EPS (ttm) | -1.87 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 51,832 |
Open | 0.445 |
Previous Close | 0.410 |
Day's Range | 0.395 - 0.450 |
52-Week Range | 0.369 - 8.100 |
Beta | 0.09 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Jul 25, 2024 |
About ALZN
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a ... [Read more]
Financial Performance
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/3/i/press4-2414520.jpg)
Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program
ATLANTA--(BUSINESS WIRE)---- $ALZN #10_day_termination_process_started--Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program.
![](https://cdn.snapi.dev/images/v1/h/0/press16-2161199.jpg)
Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement
ATLANTA--(BUSINESS WIRE)---- $ALZN #Alzamend--Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement.
![](https://cdn.snapi.dev/images/v1/p/6/press2-2127751.jpg)
Alzamend Neuro Announces Reverse Stock Split
ATLANTA--(BUSINESS WIRE)---- $ALZN #15_to_1_stock_reversal--Alzamend Neuro Announces Reverse Stock Split.
![](https://cdn.snapi.dev/images/v1/p/r/press13-1841397.jpg)
Altasciences Completes Clinical Portion of Alzamend Neuro's Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer's
LAVAL, Québec--(BUSINESS WIRE)-- #Altasciences--Altasciences is proud to support Alzamend Neuro, Inc. (Alzamend) in advancing a novel treatment for dementia related to Alzheimer's disease (Alzheimer's...
![](https://cdn.snapi.dev/images/v1/r/t/press7-1824508.jpg)
Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type
LAS VEGAS--(BUSINESS WIRE)---- $ALZN #ALZN--Ault Alliance Announces Alzamend Neuro Initiated Its Phase I/IIA Trial for Immunotherapy Vaccine ALZN002 to Treat Mild to Moderate Alzheimer's Disease
![](https://cdn.snapi.dev/images/v1/2/l/press17-1652407.jpg)
BitNile Holdings Contemplates Exchange Offer to Acquire Shares of Its Common Stock
LAS VEGAS--(BUSINESS WIRE)--BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“BitNile” or the “Company”), today announced that the Company is considering undertaking an e...
![](https://cdn.snapi.dev/images/v1/d/y/press8-1647765.jpg)
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.
NEW YORK, NY / ACCESSWIRE / November 22, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently iss...
![](https://cdn.snapi.dev/images/v1/h/j/press10-1647183.jpg)
BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period
LAS VEGAS--(BUSINESS WIRE)--BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“BitNile” or the “Company”), reported its financial results for the third quarter ended Septe...
![](https://cdn.snapi.dev/images/v1/c/n/press6-1609714.jpg)
BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer's Disease
LAS VEGAS--(BUSINESS WIRE)---- $ALZN #ALZN--BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“BitNile” or the “Company”) today announced that Alzamend Neuro, Inc. (Nasdaq: ...
![](https://cdn.snapi.dev/images/v1/o/i/press20-1554230.jpg)
Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement
ATLANTA--(BUSINESS WIRE)---- $ALZN #Alzamend--Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement
![](https://cdn.snapi.dev/images/v1/z/7/biotech9-1155204.jpg)
Alzamend Neuro Shares Are Trading Higher After Encourage Early-Stage Data From Alzheimer's Candidate
Alzamend Neuro Inc (NASDAQ: ALZN) has posted positive topline data from its Phase 1 trial for AL001 as an oral treatment for dementia-related to Alzheimer's disease. The trial was designed to determin...
![](https://cdn.snapi.dev/images/v1/s/w/biotech35-1029896.jpg)
See Why Alzamend Neuro Stock Is Rallying On Thursday
Alzamend Neuro Inc (NASDAQ: ALZN) has received a written response to its meeting request regarding the FDA's Type B Pre‑Investigational New Drug (Pre-IND) application. Today's response provides a path...
![](https://cdn.snapi.dev/images/v1/d/h/stock-market-2616931-1280-19-1029712.jpg)
Why Alzamend Neuro Shares Are Surging Higher Today
Alzamend Neuro Inc (NASDAQ: ALZN) is surging higher Thursday after the company announced it received a written response to its meeting request relating to its Type B Pre‑IND application from the FDA p...
![](https://cdn.snapi.dev/images/v1/p/r/press7-1029523.jpg)
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients' Immunological System to Combat Alzheimer's Disease
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #2nd_Treatment_to_Clinic--Alzamend Neuro Gets Positive FDA Pre-IND Response for AL002, a Therapeutic Vaccine that Seeks to Restore Patient's Immuno System to Com...
![](https://cdn.snapi.dev/images/v1/p/r/press14-1004974.jpg)
Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Initiates Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease; Doses First Participant Group
![](https://cdn.snapi.dev/images/v1/p/r/press5-946273.jpg)
Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Pursuant to the Securities Purchase Agreement with Digital Power Lending
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Receives Additional $2M Investment from Digital Power Lending Due to Its IND Application for AL001 for Dementia Related to Alzheimers
![](https://cdn.snapi.dev/images/v1/p/r/press2-937859.jpg)
Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient's Immunological System to Combat Alzheimer's
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Submits Pre-IND for AL002 as Therapeutic Vaccine That Seeks to Restore Ability of Patient's Immunological System to Combat Alzheimer's
![](https://cdn.snapi.dev/images/v1/p/r/press16-932443.jpg)
Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Disease
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Receives FDA “Study May Proceed” Letter for AL001 Phase 1 Clinical Study Investigational New Drug Application for Alzheimer's Disease
![](https://cdn.snapi.dev/images/v1/r/v/biotech8-922393.jpg)
Alzamend Neuro Stock Shoots Higher As Alzheimer's Candidate Shows Encouraging Safety Profile In Animal Models
Alzamend Neuro Inc (NASDAQ: ALZN) has announced positive toxicology results for AL002 in a toxicology study using a transgenic mouse model of Alzheimer's disease. Charles River Laboratories conducted...
![](https://cdn.snapi.dev/images/v1/p/r/press20-923785.jpg)
Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer's Disease
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Receives Positive Results for AL002, a Mutant-Peptide Vaccine, in GLP CRL Tox Study Using Alzheimer's Disease Transgenic Mouse Model
![](https://cdn.snapi.dev/images/v1/o/b/press4-902282.jpg)
Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today
TAMPA, Fla.--(BUSINESS WIRE)---- $ALZN #505b2--Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today at 9:15am ET; Alzamend Celebrates Successful Initial Public Offering and Corporate Milestone
![](https://cdn.snapi.dev/images/v1/x/i/biotech6-891473.jpg)
Alzamend Neuro Submits IND Application For Alzheimer's-Related Dementia Candidate
Ault Global Holdings Inc (NYSE: DPW), a diversified holding company, has announced that Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug application to the FDA for a Phase 1...
![](https://cdn.snapi.dev/images/v1/p/r/press20-892365.jpg)
Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer's Disease
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #505b2--Alzamend Neuro Submits IND Application to the FDA for AL001, a lithium-based ionic cocrystal oral therapy for Dementia Related to Alzheimer's Disease
![](https://cdn.snapi.dev/images/v1/p/r/press7-873744.jpg)
Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million
TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #ADDF--Alzamend Neuro Announces Closing of Initial Public Offering & Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million
![](https://cdn.snapi.dev/images/v1/p/r/press20-870346.jpg)
Ault Global Holdings Announces Alzamend Neuro Pricing of Initial Public Offering
LAS VEGAS--(BUSINESS WIRE)---- $AGH #AP--Ault Global Holdings Announces Alzamend Neuro (Nasdaq: ALZN) Pricing of Initial Public Offering of 2,500,000 Shares of Common Stock at $5.00 per Share